Taken together, our findings support the hypothesis that L3MBTL1 knockdown in NSCLC cells improves Osimertinib sensitivity while L3MBTL1 overexpression confers resistance to Osimertinib. Here, L3MBTL1 is linked to non-small cell lung carcinoma.